Lunit to Participate in American Association for Cancer Research for Eighth Consecutive Year

Six Research Abstracts to Be Presented

Medical artificial intelligence (AI) company Lunit announced on the 18th that it will participate in the "American Association for Cancer Research 2026 (AACR 2026)" to be held in San Diego, USA from April 17 to 22, 2026, where it will present six research studies utilizing its AI biomarker platform, "Lunit SCOPE."

Lunit has been participating in the AACR, which is recognized as one of the world's top three cancer conferences alongside the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), for eight consecutive years since 2019, continuously presenting research results related to Lunit SCOPE. In particular, the company has recently announced a series of joint research achievements with global pharmaceutical companies and medical institutions, consistently demonstrating that its AI biomarker technology can contribute to treatment decisions for actual cancer patients.

At this year’s conference, Lunit will present: ▲ a comparative study of digital and AI algorithms for quantitative analysis of HER2 low/ultra-low expression in metastatic breast cancer clinical samples; ▲ a study on the correlation between c-MET expression and the tumor microenvironment in non-small cell lung cancer using AI; ▲ prediction of response to tucatinib plus trastuzumab combination therapy using HER2 expression and tumor-infiltrating lymphocytes (TILs) in HER2-positive metastatic colorectal cancer; ▲ quantitative assessment of intra-tumoral and stromal tumor-infiltrating lymphocytes (iTIL, sTIL) in non-small cell lung cancer using AI and analysis of their association with immunotherapy response; ▲ identification of 19 co-expressed protein pairs for bispecific antibody development through AI-based analysis of millions of immunohistochemistry (IHC) images; and ▲ a biomarker study for predicting drug response in liver cancer patients using AI-based IHC analysis.

Lunit CEO Seo Bumseok stated, "Eight years ago, when we first stood at AACR, we had to prove whether AI could be used in cancer treatment. Now, the question itself has changed to 'How far can we go with AI biomarkers?' We will continue to improve both the quality and speed of our research so that AI biomarkers can become a core tool contributing to actual patient treatment decisions."

Meanwhile, the American Association for Cancer Research (AACR), first established in 1907, is the world’s largest academic organization for cancer-related medical science, introducing a wide range of cancer research achievements globally. It has more than 61,000 members from approximately 140 countries. Tens of thousands of people from the global medical industry and academia participate in its annual conference, and last year, more than 22,000 people from 85 countries attended.

This content was produced with the assistance of AI translation services.